Table 2. Open in new tab Study...

		Gender	Region	Race/Ethnicity
CYP3A5 phenotype
expresser (n = 56)	34 (19–55)	35	21	32	23	1	40	11	1	1	3
non-expresser (n = 28)	34 (22–59)	21	7	22	1	5	4	16	5	2	1
CYP3A5 genotype
1/1 (n = 17)	36 (22–55)	7	10	8	9	0	14	2	0	1	0
1/3 (n = 25)	31 (23–48)	17	8	20	4	1	12	9	1	0	3
1/6 (n = 15)	39 (19–51)	12	3	5	10	0	14	1	0	0	0
3/3 (n = 24)	33 (22–59)	18	6	19	0	5	2	14	5	2	1
6/6 (n = 1)	36	0	1	0	1	0	1	0	0	0	0
3/6 (n = 2)	34 (34–35)	2	0	2	0	0	1	1	0	0	0
ABCB1 (C-G-C copies)
0 (n = 17)	33 (22–59)	13	4	14	0	3	1	11	3	0	2
1 (n = 28)	31 (19–55)	20	8	21	5	2	10	11	2	3	2
2 (n = 39)	35 (19–51)	23	16	19	19	1	33	5	1	0	0
SLCO1B1 c.388
AA (n = 17)	33 (19–59)	13	4	14	0	3	2	10	3	0	2
AG (n = 18)	32 (23–55)	14	4	13	3	2	6	8	2	1	1
GG (n = 49)	35 (19–51)	29	20	27	21	1	36	9	1	2	1
SLCO1B1 c.521
TT (n = 70)	34 (19–59)	46	24	43	23	4	41	18	4	3	4
TC (n = 14)	36 (19–55)	10	4	11	1	2	3	9	2	0	0
CC (n = 0)		0	0	0	0	0	0	0	0	0	0
NR1I2 g.44477
TT (n = 37)	34 (19–55)	20	17	21	15	1	31	2	1	1	2
TC (n = 34)	34 (22–59)	25	9	22	9	3	13	17	3	0	1
CC (n = 13)	39 (24–47)	11	2	11	0	2	0	8	2	2	1
NR1I2 g.63396
CC (n = 33)	34 (19–59)	22	11	19	10	4	17	11	4	0	1
CT (n = 34)	37 (19–48)	22	12	20	12	2	22	8	2	1	1
TT (n = 17)	32 (22–55)	12	5	15	2	0	5	8	0	2	2
NR1I2 g.69789
AA (n = 54)	34 (19–55)	33	21	32	22	0	41	9	0	2	2
AG (n = 14)	34 (22–59)	12	2	11	2	1	3	8	1	1	1
GG (n = 16)	32 (24–47)	11	5	11	0	5	0	10	5	0	1

Gender

Region

Race/Ethnicity

Age, median (range)

male (n = 56)

female (n = 28)

USA (n = 54)

South Africa (n = 24)

Peru (n = 6)

Black Af/AA (n = 44)

White (n = 27)

Mestizo (n = 6)

Am Ind/Haw/PI (n = 3)

>1 race or unknown (n = 4)

CYP3A5 phenotype

expresser (n = 56)

34 (19–55)

non-expresser (n = 28)

34 (22–59)

CYP3A5 genotype

*1/*1 (n = 17)

36 (22–55)

*1/*3 (n = 25)

31 (23–48)

*1/*6 (n = 15)

39 (19–51)

*3/*3 (n = 24)

33 (22–59)

*6/*6 (n = 1)

*3/*6 (n = 2)

34 (34–35)

ABCB1 (C-G-C copies)

0 (n = 17)

33 (22–59)

1 (n = 28)

31 (19–55)

2 (n = 39)

35 (19–51)

SLCO1B1 c.388

AA (n = 17)

33 (19–59)

AG (n = 18)

32 (23–55)

GG (n = 49)

35 (19–51)

SLCO1B1 c.521

TT (n = 70)

34 (19–59)

TC (n = 14)

36 (19–55)

CC (n = 0)

NR1I2 g.44477

TT (n = 37)

34 (19–55)

TC (n = 34)

34 (22–59)

CC (n = 13)

39 (24–47)

NR1I2 g.63396

CC (n = 33)

34 (19–59)

CT (n = 34)

37 (19–48)

TT (n = 17)

32 (22–55)

NR1I2 g.69789

AA (n = 54)

34 (19–55)

AG (n = 14)

34 (22–59)

GG (n = 16)

32 (24–47)

		Gender	Region	Race/Ethnicity
CYP3A5 phenotype
expresser (n = 56)	34 (19–55)	35	21	32	23	1	40	11	1	1	3
non-expresser (n = 28)	34 (22–59)	21	7	22	1	5	4	16	5	2	1
CYP3A5 genotype
1/1 (n = 17)	36 (22–55)	7	10	8	9	0	14	2	0	1	0
1/3 (n = 25)	31 (23–48)	17	8	20	4	1	12	9	1	0	3
1/6 (n = 15)	39 (19–51)	12	3	5	10	0	14	1	0	0	0
3/3 (n = 24)	33 (22–59)	18	6	19	0	5	2	14	5	2	1
6/6 (n = 1)	36	0	1	0	1	0	1	0	0	0	0
3/6 (n = 2)	34 (34–35)	2	0	2	0	0	1	1	0	0	0
ABCB1 (C-G-C copies)
0 (n = 17)	33 (22–59)	13	4	14	0	3	1	11	3	0	2
1 (n = 28)	31 (19–55)	20	8	21	5	2	10	11	2	3	2
2 (n = 39)	35 (19–51)	23	16	19	19	1	33	5	1	0	0
SLCO1B1 c.388
AA (n = 17)	33 (19–59)	13	4	14	0	3	2	10	3	0	2
AG (n = 18)	32 (23–55)	14	4	13	3	2	6	8	2	1	1
GG (n = 49)	35 (19–51)	29	20	27	21	1	36	9	1	2	1
SLCO1B1 c.521
TT (n = 70)	34 (19–59)	46	24	43	23	4	41	18	4	3	4
TC (n = 14)	36 (19–55)	10	4	11	1	2	3	9	2	0	0
CC (n = 0)		0	0	0	0	0	0	0	0	0	0
NR1I2 g.44477
TT (n = 37)	34 (19–55)	20	17	21	15	1	31	2	1	1	2
TC (n = 34)	34 (22–59)	25	9	22	9	3	13	17	3	0	1
CC (n = 13)	39 (24–47)	11	2	11	0	2	0	8	2	2	1
NR1I2 g.63396
CC (n = 33)	34 (19–59)	22	11	19	10	4	17	11	4	0	1
CT (n = 34)	37 (19–48)	22	12	20	12	2	22	8	2	1	1
TT (n = 17)	32 (22–55)	12	5	15	2	0	5	8	0	2	2
NR1I2 g.69789
AA (n = 54)	34 (19–55)	33	21	32	22	0	41	9	0	2	2
AG (n = 14)	34 (22–59)	12	2	11	2	1	3	8	1	1	1
GG (n = 16)	32 (24–47)	11	5	11	0	5	0	10	5	0	1

Table 2.

Open in new tab

Study population genotype characteristics (n = 84)

		Gender		Region			Race/Ethnicity
	Age, median (range)	male (n = 56)	female (n = 28)	USA (n = 54)	South Africa (n = 24)	Peru (n = 6)	Black Af/AA (n = 44)	White (n = 27)	Mestizo (n = 6)	Am Ind/Haw/PI (n = 3)	>1 race or unknown (n = 4)
CYP3A5 phenotype
expresser (n = 56)	34 (19–55)	35	21	32	23	1	40	11	1	1	3
non-expresser (n = 28)	34 (22–59)	21	7	22	1	5	4	16	5	2	1
CYP3A5 genotype
1/1 (n = 17)	36 (22–55)	7	10	8	9	0	14	2	0	1	0
1/3 (n = 25)	31 (23–48)	17	8	20	4	1	12	9	1	0	3
1/6 (n = 15)	39 (19–51)	12	3	5	10	0	14	1	0	0	0
3/3 (n = 24)	33 (22–59)	18	6	19	0	5	2	14	5	2	1
6/6 (n = 1)	36	0	1	0	1	0	1	0	0	0	0
3/6 (n = 2)	34 (34–35)	2	0	2	0	0	1	1	0	0	0
ABCB1 (C-G-C copies)
0 (n = 17)	33 (22–59)	13	4	14	0	3	1	11	3	0	2
1 (n = 28)	31 (19–55)	20	8	21	5	2	10	11	2	3	2
2 (n = 39)	35 (19–51)	23	16	19	19	1	33	5	1	0	0
SLCO1B1 c.388
AA (n = 17)	33 (19–59)	13	4	14	0	3	2	10	3	0	2
AG (n = 18)	32 (23–55)	14	4	13	3	2	6	8	2	1	1
GG (n = 49)	35 (19–51)	29	20	27	21	1	36	9	1	2	1
SLCO1B1 c.521
TT (n = 70)	34 (19–59)	46	24	43	23	4	41	18	4	3	4
TC (n = 14)	36 (19–55)	10	4	11	1	2	3	9	2	0	0
CC (n = 0)		0	0	0	0	0	0	0	0	0	0
NR1I2 g.44477
TT (n = 37)	34 (19–55)	20	17	21	15	1	31	2	1	1	2
TC (n = 34)	34 (22–59)	25	9	22	9	3	13	17	3	0	1
CC (n = 13)	39 (24–47)	11	2	11	0	2	0	8	2	2	1
NR1I2 g.63396
CC (n = 33)	34 (19–59)	22	11	19	10	4	17	11	4	0	1
CT (n = 34)	37 (19–48)	22	12	20	12	2	22	8	2	1	1
TT (n = 17)	32 (22–55)	12	5	15	2	0	5	8	0	2	2
NR1I2 g.69789
AA (n = 54)	34 (19–55)	33	21	32	22	0	41	9	0	2	2
AG (n = 14)	34 (22–59)	12	2	11	2	1	3	8	1	1	1
GG (n = 16)	32 (24–47)	11	5	11	0	5	0	10	5	0	1

		Gender		Region			Race/Ethnicity
	Age, median (range)	male (n = 56)	female (n = 28)	USA (n = 54)	South Africa (n = 24)	Peru (n = 6)	Black Af/AA (n = 44)	White (n = 27)	Mestizo (n = 6)	Am Ind/Haw/PI (n = 3)	>1 race or unknown (n = 4)
CYP3A5 phenotype
expresser (n = 56)	34 (19–55)	35	21	32	23	1	40	11	1	1	3
non-expresser (n = 28)	34 (22–59)	21	7	22	1	5	4	16	5	2	1
CYP3A5 genotype
1/1 (n = 17)	36 (22–55)	7	10	8	9	0	14	2	0	1	0
1/3 (n = 25)	31 (23–48)	17	8	20	4	1	12	9	1	0	3
1/6 (n = 15)	39 (19–51)	12	3	5	10	0	14	1	0	0	0
3/3 (n = 24)	33 (22–59)	18	6	19	0	5	2	14	5	2	1
6/6 (n = 1)	36	0	1	0	1	0	1	0	0	0	0
3/6 (n = 2)	34 (34–35)	2	0	2	0	0	1	1	0	0	0
ABCB1 (C-G-C copies)
0 (n = 17)	33 (22–59)	13	4	14	0	3	1	11	3	0	2
1 (n = 28)	31 (19–55)	20	8	21	5	2	10	11	2	3	2
2 (n = 39)	35 (19–51)	23	16	19	19	1	33	5	1	0	0
SLCO1B1 c.388
AA (n = 17)	33 (19–59)	13	4	14	0	3	2	10	3	0	2
AG (n = 18)	32 (23–55)	14	4	13	3	2	6	8	2	1	1
GG (n = 49)	35 (19–51)	29	20	27	21	1	36	9	1	2	1
SLCO1B1 c.521
TT (n = 70)	34 (19–59)	46	24	43	23	4	41	18	4	3	4
TC (n = 14)	36 (19–55)	10	4	11	1	2	3	9	2	0	0
CC (n = 0)		0	0	0	0	0	0	0	0	0	0
NR1I2 g.44477
TT (n = 37)	34 (19–55)	20	17	21	15	1	31	2	1	1	2
TC (n = 34)	34 (22–59)	25	9	22	9	3	13	17	3	0	1
CC (n = 13)	39 (24–47)	11	2	11	0	2	0	8	2	2	1
NR1I2 g.63396
CC (n = 33)	34 (19–59)	22	11	19	10	4	17	11	4	0	1
CT (n = 34)	37 (19–48)	22	12	20	12	2	22	8	2	1	1
TT (n = 17)	32 (22–55)	12	5	15	2	0	5	8	0	2	2
NR1I2 g.69789
AA (n = 54)	34 (19–55)	33	21	32	22	0	41	9	0	2	2
AG (n = 14)	34 (22–59)	12	2	11	2	1	3	8	1	1	1
GG (n = 16)	32 (24–47)	11	5	11	0	5	0	10	5	0	1

Black Af, Black African; AA, African American; Am Ind, American Indian; Haw, Native Hawaiian; PI, Pacific Islander.

This Feature Is Available To Subscribers Only